These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 1949948)

  • 1. Accumulation of 3-hydroxyquinidine following chronic quinidine therapy.
    Ackerman BH; Olsen KM; Pappas AA
    DICP; 1991; 25(7-8):867-9. PubMed ID: 1949948
    [No Abstract]   [Full Text] [Related]  

  • 2. Disposition of 3-hydroxyquinidine in patients receiving initial intravenous quinidine gluconate for electrophysiology testing of ventricular tachycardia.
    Ackerman BH; Olsen KM; Kennedy EE; Taylor EH; Chen BH; Jordan D; Ackerman DJ
    DICP; 1989 May; 23(5):375-8. PubMed ID: 2728524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fetal supraventricular tachycardia treated with high-dose quinidine: toxicity associated with marked elevation of the metabolite, 3(S)-3-hydroxyquinidine.
    Killeen AA; Bowers LD
    Obstet Gynecol; 1987 Sep; 70(3 Pt 2):445-9. PubMed ID: 3627599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Elimination half-life of 3-hydroxyquinidine in man].
    Camsonne R; Moulin MA; Bazin C; Charbonneau P; Drieu L; Pedailles S; Briand A
    Therapie; 1983; 38(1):115-6. PubMed ID: 6867995
    [No Abstract]   [Full Text] [Related]  

  • 5. Total and unbound concentrations of quinidine and 3-hydroxyquinidine at steady state.
    Wooding-Scott RA; Visco J; Slaughter RL
    Am Heart J; 1987 Feb; 113(2 Pt 1):302-6. PubMed ID: 3812182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elimination kinetic of high polar metabolites pool of quinidine from human serum.
    Camsonne R; Moulin MA; Charbonneau P; Bazin C
    Int J Clin Pharmacol Ther Toxicol; 1985 Feb; 23(2):74-5. PubMed ID: 3988396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of coadministration of verapamil on the pharmacokinetics and metabolism of quinidine.
    Edwards DJ; Lavoie R; Beckman H; Blevins R; Rubenfire M
    Clin Pharmacol Ther; 1987 Jan; 41(1):68-73. PubMed ID: 3802708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quinidine as a probe for CYP3A4 activity: intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6.
    Damkier P; Brøsen K
    Clin Pharmacol Ther; 2000 Aug; 68(2):199-209. PubMed ID: 10976551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacokinetics and pharmacodynamics of quinidine and 3-hydroxyquinidine.
    Wooding-Scott RA; Smalley J; Visco J; Slaughter RL
    Br J Clin Pharmacol; 1988 Oct; 26(4):415-21. PubMed ID: 3190991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contribution of quinidine metabolites to electrophysiologic responses in human subjects.
    Kavanagh KM; Wyse DG; Mitchell LB; Gilhooly T; Gillis AM; Duff HJ
    Clin Pharmacol Ther; 1989 Sep; 46(3):352-8. PubMed ID: 2776394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma concentrations of quinidine, its major metabolites, and dihydroquinidine in patients with torsades de pointes.
    Thompson KA; Murray JJ; Blair IA; Woosley RL; Roden DM
    Clin Pharmacol Ther; 1988 Jun; 43(6):636-42. PubMed ID: 3378385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and metabolism of quinidine in extensive and poor metabolisers of sparteine.
    Mikus G; Ha HR; Vozeh S; Zekorn C; Follath F; Eichelbaum M
    Eur J Clin Pharmacol; 1986; 31(1):69-72. PubMed ID: 3780830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A high-pressure liquid chromatography method for serum quinidine and (3S)-3-hydroxyquinidine.
    Weidner N; Ladenson JH; Larson L; Kessler G; McDonald JM
    Clin Chim Acta; 1979 Jan; 91(1):7-13. PubMed ID: 761394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence supporting 3(S)-3-hydroxyquinidine-associated cardiotoxicity.
    Bowers LD; Nelson KM; Connor R; Lais CJ; Krauss E
    Ther Drug Monit; 1985; 7(3):308-12. PubMed ID: 4049469
    [No Abstract]   [Full Text] [Related]  

  • 15. Antiarrhythmic activity of two quinidine metabolites in experimental reperfusion arrhythmia: relative potency and pharmacodynamic interaction with the parent drug.
    Vozeh S; Oti-Amoako K; Uematsu T; Follath F
    J Pharmacol Exp Ther; 1987 Oct; 243(1):297-301. PubMed ID: 3668860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reverse-phase liquid chromatography and pharmacokinetic study of two hydroxylated analogues of quinidine in dogs.
    Leroyer R; Jarreau C; Pays M; Varoquaux O; Advenier C
    J Pharm Sci; 1984 Jun; 73(6):844-6. PubMed ID: 6547483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disposition kinetics of dihydroquinidine following quinidine administration.
    Ueda CT; Williamson BJ; Dzindzio BS
    Res Commun Chem Pathol Pharmacol; 1976 Jun; 14(2):215-25. PubMed ID: 940955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of fluvoxamine on the pharmacokinetics of quinidine.
    Damkier P; Hansen LL; Brøsen K
    Eur J Clin Pharmacol; 1999 Aug; 55(6):451-6. PubMed ID: 10492058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of effect of smoking on the metabolism and pharmacokinetics of quinidine in patients.
    Edwards DJ; Axelson JE; Visco JP; vanEvery S; Slaughter RL; Lalka D
    Br J Clin Pharmacol; 1987 Mar; 23(3):351-4. PubMed ID: 3567051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of quinidine gluconate for nonlinear kinetics following chronic dosing.
    Russo J; Russo ME; Smith RA; Pershing LK
    J Clin Pharmacol; 1982; 22(5-6):264-70. PubMed ID: 7107973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.